Skip to main content
Top
Published in: International Journal of Clinical Oncology 2/2016

01-04-2016 | Original Article

Growth rate of chemotherapy-naïve lung metastasis from colorectal cancer could be a predictor of early relapse after lung resection

Authors: Koji Kawaguchi, Keisuke Uehara, Goro Nakayama, Takayuki Fukui, Koichi Fukumoto, Shota Nakamura, Kohei Yokoi

Published in: International Journal of Clinical Oncology | Issue 2/2016

Login to get access

Abstract

Purpose

The aim of this study was to elucidate a potential risk factor for early relapse after pulmonary metastasectomy of colorectal cancer and to propose an optimal treatment strategy for lung metastasis with an aggressive nature.

Methods

Seventy patients who underwent pulmonary metastasectomy for diachronically measurable pulmonary lesions were retrospectively analyzed. We calculated the tumor doubling time (TDT) as the growth rate of lung metastasis and divided the study population into two groups: Rapid (TDT ≤ 100 days) and Slow (TDT > 100 days).

Results

The patients consisted of 47 males and 23 females, with a mean age of 63 years. Forty-two patients had a relapse after pulmonary metastasectomy with a median follow-up duration of 24 months. There was a significant difference in relapse-free survival between the Rapid and Slow groups (p = 0.047). Using a multivariate analysis, no preoperative chemotherapy and a high level of serum carcinoembryonic antigen were proven to be significant risk factors for relapse after metastasectomy. Meanwhile, multivariate analyses among 37 patients without preoperative chemotherapy indicated that TDT was the sole significant factor for relapse-free survival. In addition, eight of nine patients with relapse within 12 months were placed into the Rapid group.

Conclusions

Although this was a preliminary study with a small number of patients, it suggested that lung metastases demonstrating a TDT of 100 days or less have a high risk of early relapse after metastasectomy.
Appendix
Available only for authorised users
Literature
1.
go back to reference Onaitis MW, Petersen RP, Haney JC et al (2009) Prognostic factors for recurrence after pulmonary resection of colorectal cancer metastases. Ann Thorac Surg 87:1684–1688CrossRefPubMed Onaitis MW, Petersen RP, Haney JC et al (2009) Prognostic factors for recurrence after pulmonary resection of colorectal cancer metastases. Ann Thorac Surg 87:1684–1688CrossRefPubMed
2.
go back to reference Iida T, Nomori H, Shiba M et al (2013) Prognostic factors after pulmonary metastasectomy for colorectal cancer and rationale for determining surgical indications: a retrospective analysis. Ann Surg 257:1059–1064CrossRefPubMed Iida T, Nomori H, Shiba M et al (2013) Prognostic factors after pulmonary metastasectomy for colorectal cancer and rationale for determining surgical indications: a retrospective analysis. Ann Surg 257:1059–1064CrossRefPubMed
3.
go back to reference Nordlinger B, Sorbye H, Glimelius B et al (2008) Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371:1007–1016CrossRefPubMedPubMedCentral Nordlinger B, Sorbye H, Glimelius B et al (2008) Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371:1007–1016CrossRefPubMedPubMedCentral
4.
go back to reference Usuda K, Saito Y, Sagawa M et al (1994) Tumor doubling time and prognostic assessment of patients with primary lung cancer. Cancer 74:2239–2244CrossRefPubMed Usuda K, Saito Y, Sagawa M et al (1994) Tumor doubling time and prognostic assessment of patients with primary lung cancer. Cancer 74:2239–2244CrossRefPubMed
5.
go back to reference Friberg S, Mattson S (1997) On the growth rates of human malignant tumors: implications for medical decision making. J Surg Oncol 65:284–297CrossRefPubMed Friberg S, Mattson S (1997) On the growth rates of human malignant tumors: implications for medical decision making. J Surg Oncol 65:284–297CrossRefPubMed
6.
7.
go back to reference Kanemitsu Y, Kato T, Hirai T, Yasui K (2004) Preoperative probability model for predicting overall survival after resection of pulmonary metastases from colorectal cancer. Br J Surg 91:112–120CrossRefPubMed Kanemitsu Y, Kato T, Hirai T, Yasui K (2004) Preoperative probability model for predicting overall survival after resection of pulmonary metastases from colorectal cancer. Br J Surg 91:112–120CrossRefPubMed
8.
go back to reference Golfinopoulos V, Salanti G, Pavlidis N, Ioannidis JP (2007) Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis. Lancet Oncol 8:898–911CrossRefPubMed Golfinopoulos V, Salanti G, Pavlidis N, Ioannidis JP (2007) Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis. Lancet Oncol 8:898–911CrossRefPubMed
9.
go back to reference Takei H, Kondo H, Miyaoka E et al (2014) Surgery for small cell lung cancer: a retrospective analysis of 243 patients from Japanese Lung Cancer Registry in 2004. J Thorac Oncol 9:1140–1145CrossRefPubMed Takei H, Kondo H, Miyaoka E et al (2014) Surgery for small cell lung cancer: a retrospective analysis of 243 patients from Japanese Lung Cancer Registry in 2004. J Thorac Oncol 9:1140–1145CrossRefPubMed
10.
go back to reference Tjandra JJ, Chan MK (2007) Follow-up after curative resection of colorectal cancer: a meta-analysis. Dis Colon Rectum 50:1783–1799CrossRefPubMed Tjandra JJ, Chan MK (2007) Follow-up after curative resection of colorectal cancer: a meta-analysis. Dis Colon Rectum 50:1783–1799CrossRefPubMed
11.
go back to reference NCC Network. NCCN Clinical Practice Guidelines in Oncology. Version 2.2013 NCC Network. NCCN Clinical Practice Guidelines in Oncology. Version 2.2013
Metadata
Title
Growth rate of chemotherapy-naïve lung metastasis from colorectal cancer could be a predictor of early relapse after lung resection
Authors
Koji Kawaguchi
Keisuke Uehara
Goro Nakayama
Takayuki Fukui
Koichi Fukumoto
Shota Nakamura
Kohei Yokoi
Publication date
01-04-2016
Publisher
Springer Japan
Published in
International Journal of Clinical Oncology / Issue 2/2016
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-015-0889-1

Other articles of this Issue 2/2016

International Journal of Clinical Oncology 2/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine